Mark A Lemmon

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/4013850/publications.pdf

Version: 2024-02-01

		7069	8138
158	27,259	78	148
papers	citations	h-index	g-index

163	163	163	27430
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Cell Signaling by Receptor Tyrosine Kinases. Cell, 2010, 141, 1117-1134.	13.5	4,613
2	Membrane recognition by phospholipid-binding domains. Nature Reviews Molecular Cell Biology, 2008, 9, 99-111.	16.1	1,298
3	An Open-and-Shut Case? Recent Insights into the Activation of EGF/ErbB Receptors. Molecular Cell, 2003, 12, 541-552.	4.5	774
4	EGF Activates Its Receptor by Removing Interactions that Autoinhibit Ectodomain Dimerization. Molecular Cell, 2003, 11, 507-517.	4.5	675
5	Heparin-induced oligomerization of FGF molecules is responsible for FGF receptor dimerization, activation, and cell proliferation. Cell, 1994, 79, 1015-1024.	13.5	667
6	Signal-dependent membrane targeting by pleckstrin homology (PH) domains. Biochemical Journal, 2000, 350, 1-18.	1.7	656
7	Structure of the high affinity complex of inositol trisphosphate with a phospholipase C pleckstrin homology domain. Cell, 1995, 83, 1037-1046.	13.5	613
8	Specific and high-affinity binding of inositol phosphates to an isolated pleckstrin homology domain.. Proceedings of the National Academy of Sciences of the United States of America, 1995, 92, 10472-10476.	3.3	544
9	Sequence specificity in the dimerization of transmembrane .alpha.-helixes. Biochemistry, 1992, 31, 12719-12725.	1.2	520
10	Activation of phospholipase Cgamma by PI 3-kinase-induced PH domain-mediated membrane targeting. EMBO Journal, 1998, 17, 414-422.	3.5	507
11	Phosphoinositide Recognition Domains. Traffic, 2003, 4, 201-213.	1.3	500
12	Regulation of growth factor activation by proteoglycans: What is the role of the low affinity receptors?. Cell, 1995, 83, 357-360.	13.5	484
13	PH Domains: Diverse Sequences with a Common Fold Recruit Signaling Molecules to the Cell Surface. Cell, 1996, 85, 621-624.	13.5	473
14	Regulation of signal transduction and signal diversity by receptor oligomerization. Trends in Biochemical Sciences, 1994, 19, 459-463.	3.7	438
15	Specificity and Promiscuity in Phosphoinositide Binding by Pleckstrin Homology Domains. Journal of Biological Chemistry, 1998, 273, 30497-30508.	1.6	398
16	ErbB3/HER3 intracellular domain is competent to bind ATP and catalyze autophosphorylation. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 7692-7697.	3.3	395
17	The EGFR Family: Not So Prototypical Receptor Tyrosine Kinases. Cold Spring Harbor Perspectives in Biology, 2014, 6, a020768-a020768.	2.3	345
18	Structural Basis for Discrimination of 3-Phosphoinositides by Pleckstrin Homology Domains. Molecular Cell, 2000, 6, 373-384.	4.5	333

#	Article	IF	Citations
19	Identification and analysis of PH domain-containing targets of phosphatidylinositol 3-kinase using a novel in vivo assay in yeast. EMBO Journal, 1998, 17, 5374-5387.	3.5	325
20	Genome-Wide Analysis of Membrane Targeting by S. cerevisiae Pleckstrin Homology Domains. Molecular Cell, 2004, 13, 677-688.	4.5	315
21	Two EGF molecules contribute additively to stabilization of the EGFR dimer. EMBO Journal, 1997, 16, 281-294.	3.5	314
22	Svp1p defines a family of phosphatidylinositol 3,5-bisphosphate effectors. EMBO Journal, 2004, 23, 1922-1933.	3.5	302
23	ALK Mutations Confer Differential Oncogenic Activation and Sensitivity to ALK Inhibition Therapy in Neuroblastoma. Cancer Cell, 2014, 26, 682-694.	7.7	302
24	A dimerization motif for transmembrane Î±â€“helices. Nature Structural Biology, 1994, 1, 157-163.	9.7	294
25	Crystal structure at 2.2 Ã... resolution of the pleckstrin homology domain from human dynamin. Cell, 1994, 79, 199-209.	13.5	285
26	EGFR Ligands Differentially Stabilize Receptor Dimers to Specify Signaling Kinetics. Cell, 2017, 171, 683-695.e18.	13.5	276
27	Measurement of the binding of tyrosyl phosphopeptides to SH2 domains: a reappraisal.. Proceedings of the National Academy of Sciences of the United States of America, 1995, 92, 3199-3203.	3.3	273
28	The Single Transmembrane Domains of ErbB Receptors Self-associate in Cell Membranes. Journal of Biological Chemistry, 2002, 277, 4704-4712.	1.6	269
29	The Juxtamembrane Region of the EGF Receptor Functions as an Activation Domain. Molecular Cell, 2009, 34, 641-651.	4.5	262
30	Identification of the Binding Site for Acidic Phospholipids on the PH Domain of Dynamin: Implications for Stimulation of GTPase Activity. Journal of Molecular Biology, 1996, 255, 14-21.	2.0	251
31	Phosphatidylinositol-4,5-bisphosphate is required for endocytic coated vesicle formation. Current Biology, 1998, 8, 1399-1404.	1.8	247
32	Epidermal Growth Factor Receptor Dimerization and Activation Require Ligand-Induced Conformational Changes in the Dimer Interface. Molecular and Cellular Biology, 2005, 25, 7734-7742.	1.1	247
33	Signal-dependent membrane targeting by pleckstrin homology (PH) domains. Biochemical Journal, 2000, 350, 1.	1.7	230
34	Pleckstrin homology domains and the cytoskeleton. FEBS Letters, 2002, 513, 71-76.	1.3	229
35	SH2 and PTB Domains in Tyrosine Kinase Signaling. Science Signaling, 2003, 2003, re12-re12.	1.6	228
36	Erlotinib binds both inactive and active conformations of the EGFR tyrosine kinase domain. Biochemical Journal, 2012, 448, 417-423.	1.7	228

#	Article	IF	Citations
37	Functional selectivity of EGF family peptide growth factors: Implications for cancer. , 2009, 122, 1-8.		225
38	Phosphatidylinositol 3,5-bisphosphate: metabolism and cellular functions. Trends in Biochemical Sciences, 2006, 31, 52-63.	3.7	203
39	Pleckstrin homology (PH) domains and phosphoinositides. Biochemical Society Symposia, 2007, 74, 81-93.	2.7	202
40	Differential Inhibitor Sensitivity of Anaplastic Lymphoma Kinase Variants Found in Neuroblastoma. Science Translational Medicine, 2011, 3, 108ra114.	5.8	199
41	Identification of the Rac-GEF P-Rex1 as an Essential Mediator of ErbB Signaling in Breast Cancer. Molecular Cell, 2010, 40, 877-892.	4.5	194
42	Pleckstrin homology (PH) domains and phosphoinositides. Biochemical Society Symposia, 2007, 74, 81.	2.7	191
43	All Phox Homology (PX) Domains from Saccharomyces cerevisiae Specifically Recognize Phosphatidylinositol 3-Phosphate. Journal of Biological Chemistry, 2001, 276, 44179-44184.	1.6	187
44	Ligand-induced ErbB receptor dimerization. Experimental Cell Research, 2009, 315, 638-648.	1.2	185
45	Specificity and promiscuity in membrane helix interactions. Quarterly Reviews of Biophysics, 1994, 27, 157-218.	2.4	182
46	The Pleckstrin Homology Domains of Dynamin Isoforms Require Oligomerization for High Affinity Phosphoinositide Binding. Journal of Biological Chemistry, 1998, 273, 27725-27733.	1.6	182
47	The glycophorin A transmembrane domain dimer: Sequence-specific propensity for a right-handed supercoil of helixes. Biochemistry, 1992, 31, 12726-12732.	1.2	177
48	Structural Basis for Negative Cooperativity in Growth Factor Binding to an EGF Receptor. Cell, 2010, 142, 568-579.	13.5	162
49	Structures of Î²-klotho reveal a â€˜zip codeâ€™-like mechanism for endocrine FGF signalling. Nature, 2018, 553, 501-505.	13.7	160
50	Mechanism of Activation and Inhibition of the HER4/ErbB4 Kinase. Structure, 2008, 16, 460-467.	1.6	159
51	Conditional Peripheral Membrane Proteins: Facing up to Limited Specificity. Structure, 2012, 20, 15-27.	1.6	151
52	Kinase Associated-1 Domains Drive MARK/PAR1 Kinases to Membrane Targets by Binding Acidic Phospholipids. Cell, 2010, 143, 966-977.	13.5	150
53	The ALK/ROS1 Inhibitor PF-06463922 Overcomes Primary Resistance to Crizotinib in ALK-Driven Neuroblastoma. Cancer Discovery, 2016, 6, 96-107.	7.7	144
54	Argos inhibits epidermal growth factor receptor signalling by ligand sequestration. Nature, 2004, 430, 1040-1044.	13.7	127

#	Article	IF	Citations
55	Extracellular domains drive homo- but not hetero-dimerization of erbB receptors. EMBO Journal, 2000, 19, 4632-4643.	3.5	126
56	ErbB3/HER3 does not homodimerize upon neuregulin binding at the cell surface. FEBS Letters, 2004, 569, 332-336.	1.3	126
57	Normalization of nomenclature for peptide motifs as ligands of modular protein domains. FEBS Letters, 2002, 513, 141-144.	1.3	118
58	Dynamin GTPase regulation is altered by PH domain mutations found in centronuclear myopathy patients. EMBO Journal, 2010, 29, 3054-3067.	3.5	116
59	Mechanism for activation of mutated epidermal growth factor receptors in lung cancer. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, E3595-604.	3.3	116
60	Dominant-negative inhibition of receptor-mediated endocytosis by a dynamin-1 mutant with a defective pleckstrin homology domain. Current Biology, 1999, 9, 261-265.	1.8	114
61	Determining selectivity of phosphoinositide-binding domains. Methods, 2006, 39, 122-133.	1.9	114
62	Inhibition of nuclear import and cell-cycle progression by mutated forms of the dynamin-like GTPase MxB. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 8957-8962.	3.3	111
63	A structure-based model for ligand binding and dimerization of EGF receptors. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 929-934.	3.3	111
64	Palmitoylation of the EGFR Ligand Spitz by Rasp Increases Spitz Activity by Restricting Its Diffusion. Developmental Cell, 2006, 10, 167-176.	3.1	105
65	Live cell imaging with protein domains capable of recognizing phosphatidylinositol 4,5-bisphosphate; a comparative study. BMC Cell Biology, 2009, 10, 67.	3.0	105
66	N-terminal Domains Elicit Formation of Functional Pmel17 Amyloid Fibrils. Journal of Biological Chemistry, 2009, 284, 35543-35555.	1.6	101
67	Kit Receptor Dimerization Is Driven by Bivalent Binding of Stem Cell Factor. Journal of Biological Chemistry, 1997, 272, 6311-6317.	1.6	98
68	The Dark Side of Cell Signaling: Positive Roles for Negative Regulators. Cell, 2016, 164, 1172-1184.	13.5	97
69	Molecular determinants in pleckstrin homology domains that allow specific recognition of phosphoinositides. Biochemical Society Transactions, 2001, 29, 377-384.	1.6	96
70	The tethered configuration of the EGF receptor extracellular domain exerts only a limited control of receptor function. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 923-928.	3.3	96
71	Solution structure of pleckstrin homology domain of dynamin by heteronuclear NMR spectroscopy.. Proceedings of the National Academy of Sciences of the United States of America, 1995, 92, 816-820.	3.3	94
72	TIPE3 Is the Transfer Protein of Lipid Second Messengers that Promote Cancer. Cancer Cell, 2014, 26, 465-478.	7.7	93

#	Article	IF	Citations
73	On the nature of low- and high-affinity EGF receptors on living cells. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 5735-5740.	3.3	91
74	Ligand-Induced Structural Transitions in ErbB Receptor Extracellular Domains. Structure, 2007, 15, 942-954.	1.6	88
75	Nuclear Signaling by Receptor Tyrosine Kinases: The First Robin of Spring. Cell, 2006, 127, 45-48.	13.5	87
76	Role of Inn1 and its interactions with Hof1 and Cyk3 in promoting cleavage furrow and septum formation in S. cerevisiae. Journal of Cell Biology, 2009, 185, 995-1012.	2.3	87
77	Quantitative Analysis of the Effect of Phosphoinositide Interactions on the Function of Dbl Family Proteins. Journal of Biological Chemistry, 2001, 276, 45868-45875.	1.6	83
78	High-Affinity Binding of a FYVE Domain to Phosphatidylinositol 3-Phosphate Requires Intact Phospholipid but Not FYVE Domain Oligomerization. Biochemistry, 2001, 40, 8581-8587.	1.2	82
79	Essential Role for Rac in Heregulin Î²1 Mitogenic Signaling: a Mechanism That Involves Epidermal Growth Factor Receptor and Is Independent of ErbB4. Molecular and Cellular Biology, 2006, 26, 831-842.	1.1	82
80	EGF-independent activation of cell-surface EGF receptors harboring mutations found in gefitinib-sensitive lung cancer. Oncogene, 2007, 26, 1567-1576.	2.6	78
81	Complex Relationship between Ligand Binding and Dimerization in the Epidermal Growth Factor Receptor. Cell Reports, 2014, 9, 1306-1317.	2.9	78
82	Specific role for the PH domain of dynamin-1 in the regulation of rapid endocytosis in adrenal chromaffin cells. EMBO Journal, 1997, 16, 1565-1574.	3.5	75
83	Assessing the range of kinase autoinhibition mechanisms in the insulin receptor family. Biochemical Journal, 2012, 448, 213-220.	1.7	75
84	Alaâ€insertion scanning mutagenesis of the glycophorin a transmembrane helix: A rapid way to map helixâ€helix interactions in integral membrane proteins. Protein Science, 1996, 5, 1339-1341.	3.1	71
85	Dimerization of the p185neu transmembrane domain is necessary but not sufficient for transformation. Oncogene, 1997, 14, 687-696.	2.6	71
86	ErbB2 resembles an autoinhibited invertebrate epidermal growth factor receptor. Nature, 2009, 461, 287-291.	13.7	69
87	Thermodynamic Studies of Tyrosyl-Phosphopeptide Binding to the SH2 Domain of p56lck. Biochemistry, 1994, 33, 5070-5076.	1.2	68
88	Receptor tyrosine kinases with intracellular pseudokinase domains. Biochemical Society Transactions, 2013, 41, 1029-1036.	1.6	68
89	Crystal Structure of Fibroblast Growth Factor 9 Reveals Regions Implicated in Dimerization and Autoinhibition. Journal of Biological Chemistry, 2001, 276, 4322-4329.	1.6	62
90	Antibody targeting of anaplastic lymphoma kinase induces cytotoxicity of human neuroblastoma. Oncogene, 2012, 31, 4859-4867.	2.6	61

#	Article	IF	Citations
91	Scratching the surface with the PH domain. Nature Structural and Molecular Biology, 1995, 2, 715-718.	3.6	59
92	The Role of the Pleckstrin Homology Domain in Membrane Targeting and Activation of Phospholipase Cî²1. Journal of Biological Chemistry, 2000, 275, 14873-14881.	1.6	59
93	Loss of Phosphatidylinositol 3-Phosphate Binding by the C-terminal Tiam-1 Pleckstrin Homology Domain Prevents in Vivo Rac1 Activation without Affecting Membrane Targeting. Journal of Biological Chemistry, 2003, 278, 11457-11464.	1.6	59
94	The p21-activated Protein Kinase-related Kinase Cla4 Is a Coincidence Detector of Signaling by Cdc42 and Phosphatidylinositol 4-Phosphate. Journal of Biological Chemistry, 2004, 279, 17101-17110.	1.6	57
95	Membrane activity of the phospholipase C-Î´1 pleckstrin homology (PH) domain. Biochemical Journal, 2005, 389, 435-441.	1.7	56
96	Structural Insights into Pseudokinase Domains of Receptor Tyrosine Kinases. Molecular Cell, 2020, 79, 390-405.e7.	4.5	56
97	Helix-helix interactions inside lipid bilayers. Current Opinion in Structural Biology, 1992, 2, 511-518.	2.6	55
98	A possible effector role for the pleckstrin homology (PH) domain of dynamin. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 13359-13364.	3.3	55
99	Specificity and promiscuity in membrane helix interactions. FEBS Letters, 1994, 346, 17-20.	1.3	54
100	Structural basis for EGFR ligand sequestration by Argos. Nature, 2008, 453, 1271-1275.	13.7	48
101	Mutations in or near the Transmembrane Domain Alter PMEL Amyloid Formation from Functional to Pathogenic. PLoS Genetics, 2011, 7, e1002286.	1.5	46
102	Drug Sensitivity and Allele Specificity of First-Line Osimertinib Resistance EGFR Mutations. Cancer Research, 2020, 80, 2017-2030.	0.4	46
103	Phosphoinositide Binding by the Pleckstrin Homology Domains of Ipl and Tih1. Journal of Biological Chemistry, 2002, 277, 49935-49944.	1.6	45
104	Finding the missing links in EGFR. Nature Structural and Molecular Biology, 2012, 19, 1-3.	3.6	45
105	Kinetics of receptor tyrosine kinase activation define ERK signaling dynamics. Science Signaling, 2020, 13, .	1.6	45
106	Loss of pleckstrin defines a novel pathway for PKC-mediated exocytosis. Blood, 2009, 113, 3577-3584.	0.6	44
107	Putting together structures of epidermal growth factor receptors. Current Opinion in Structural Biology, 2014, 29, 95-101.	2.6	44
108	The Dbs PH domain contributes independently to membrane targeting and regulation of guanine nucleotide-exchange activity. Biochemical Journal, 2006, 400, 563-572.	1.7	42

#	Article	IF	Citations
109	Comparison of Saccharomyces cerevisiae F-BAR Domain Structures Reveals a Conserved Inositol Phosphate Binding Site. Structure, 2015, 23, 352-363.	1.6	40
110	The EGFR Exon 19 Mutant L747-A750>P Exhibits Distinct Sensitivity to Tyrosine Kinase Inhibitors in Lung Adenocarcinoma. Clinical Cancer Research, 2019, 25, 6382-6391.	3.2	39
111	Computational analysis of EGFR inhibition by Argos. Developmental Biology, 2005, 284, 523-535.	0.9	37
112	Pleckstrin Homology Domains: Two Halves Make a Hole?. Cell, 2005, 120, 574-576.	13.5	36
113	Glioblastoma mutations alter EGFR dimer structure to prevent ligand bias. Nature, 2022, 602, 518-522.	13.7	36
114	Thermodynamic Studies of SHC Phosphotyrosine Interaction Domain Recognition of the NPXpY Motif. Journal of Biological Chemistry, 1996, 271, 4770-4775.	1.6	33
115	Specificity of the Myotubularin Family of Phosphatidylinositol-3-phosphatase Is Determined by the PH/GRAM Domain. Journal of Biological Chemistry, 2006, 281, 31762-31769.	1.6	32
116	Ligand regulation of a constitutively dimeric EGF receptor. Nature Communications, 2015, 6, 7380.	5.8	31
117	Insulin and epidermal growth factor receptor family members share parallel activation mechanisms. Protein Science, 2020, 29, 1331-1344.	3.1	31
118	Overcoming resistance to HER2 inhibitors through state-specific kinase binding. Nature Chemical Biology, 2016, 12, 923-930.	3.9	29
119	Dimerization of Tie2 mediated by its membrane-proximal FNIII domains. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 4382-4387.	3.3	29
120	Molecular dynamics analysis of conserved hydrophobic and hydrophilic bond-interaction networks in ErbB family kinases. Biochemical Journal, 2011, 436, 241-251.	1.7	27
121	Drugging the â€œUndruggableâ€•MYCN Oncogenic Transcription Factor: Overcoming Previous Obstacles to Impact Childhood Cancers. Cancer Research, 2021, 81, 1627-1632.	0.4	25
122	Molecular determinants of KA1 domain-mediated autoinhibition and phospholipid activation of MARK1 kinase. Biochemical Journal, 2017, 474, 385-398.	1.7	21
123	Non-acylated Wnts Can Promote Signaling. Cell Reports, 2019, 26, 875-883.e5.	2.9	21
124	Structural basis for ligand reception by anaplastic lymphoma kinase. Nature, 2021, 600, 148-152.	13.7	21
125	Phosphatidylserine binding directly regulates TIM-3 function. Biochemical Journal, 2021, 478, 3331-3349.	1.7	19
126	The EGF Receptor Family as Therapeutic Targets in Breast Cancer. Breast Disease, 2003, 18, 33-43.	0.4	18

#	Article	IF	Citations
127	Genome-wide analysis of signaling domain function. Current Opinion in Chemical Biology, 2003, 7, 103-109.	2.8	15
128	Structural Basis for MARK1 Kinase Autoinhibition by Its KA1 Domain. Structure, 2018, 26, 1137-1143.e3.	1.6	15
129	Specificity of the Myotubularin Family of Phosphatidylinositol-3-phosphatase Is Determined by the PH/GRAM Domain. Journal of Biological Chemistry, 2006, 281, 31762-31769.	1.6	14
130	A New Twist in the Transmembrane Signaling Tool-Kit. Cell, 2007, 130, 213-215.	13.5	13
131	ROR and RYK extracellular region structures suggest that receptor tyrosine kinases have distinct WNT-recognition modes. Cell Reports, 2021, 37, 109834.	2.9	13
132	<scp>EGFR</scp> mutations cause a lethal syndrome of epithelial dysfunction with progeroid features. Molecular Genetics & Genomic Medicine, 2015, 3, 452-458.	0.6	12
133	[48] Analysis of phosphoinositide binding by Pleckstrin homology domain from dynamin. Methods in Enzymology, 2001, 329, 457-468.	0.4	11
134	Computational algorithms for in silico profiling of activating mutations in cancer. Cellular and Molecular Life Sciences, 2019, 76, 2663-2679.	2.4	11
135	Protein Kinase C Regulation: C1 Meets C-tail. Structure, 2011, 19, 144-146.	1.6	10
136	KSR Plays CRAF-ty. Science, 2011, 332, 1043-1044.	6.0	9
137	Neuregulin Signaling Is a Mechanism of Therapeutic Resistance in Head and Neck Squamous Cell Carcinoma. Molecular Cancer Therapeutics, 2019, 18, 2124-2134.	1.9	9
138	Looking lively: emerging principles of pseudokinase signaling. Trends in Biochemical Sciences, 2022, 47, 875-891.	3.7	9
139	Occupy EGFR: Figure 1.. Cancer Discovery, 2012, 2, 398-400.	7.7	8
140	Argos Mutants Define an Affinity Threshold for Spitz Inhibition in Vivo. Journal of Biological Chemistry, 2006, 281, 28993-29001.	1.6	6
141	Deletion Mutations Keep Kinase Inhibitors in the Loop. Cancer Cell, 2016, 29, 423-425.	7.7	5
142	Regulation of Kinase Activity in the Caenorhabditis elegans EGF Receptor, LET-23. Structure, 2018, 26, 270-281.e4.	1.6	5
143	Flipping ATP to AMPlify Kinase Functions. Cell, 2018, 175, 641-642.	13.5	4
144	Comparison of tyrosine kinase domain properties for the neurotrophin receptors TrkA and TrkB. Biochemical Journal, 2020, 477, 4053-4070.	1.7	4

#	Article	IF	Citations
145	Smoothening out the patches. Science, 2018, 362, 26-27.	6.0	3
146	Computational studies of anaplastic lymphoma kinase mutations reveal common mechanisms of oncogenic activation. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, e2019132118.	3.3	3
147	PH Domains. , 2005, , 337-363.		2
148	Pleckstrin Homology (PH) Domains. , 2010, , 1093-1101.		2
149	Dynamics of protein kinases and pseudokinases by HDX-MS. Methods in Enzymology, 2022, 667, 303-338.	0.4	2
150	Structural bases for specific phosphoinositide binding by PH domains. Biochemical Society Transactions, 1999, 27, A73-A73.	1.6	0
151	Pleckstrin Homology (PH) Domains. , 2003, , 161-169.		0
152	Autoâ€inhibition of dynamin GTPase activity is regulated by PH domain interactions. FASEB Journal, 2009, 23, 697.3.	0.2	0
153	Regulation of the epidermal growth factor receptor intracellular domain. FASEB Journal, 2009, 23, 883.2.	0.2	0
154	Structural basis for EGFR ligand sequestration by Argos. FASEB Journal, 2009, 23, 883.7.	0.2	0
155	ErbB2/HER2/Neu resembles an autoinhibited invertebrate EGF receptor. FASEB Journal, 2009, 23, 884.3.	0.2	0
156	Phosphoinositideâ€mimicking peptide sequences are binding targets for PH domains. FASEB Journal, 2009, 23, 873.7.	0.2	0
157	Characterization of Novel PtdIns(4,5)P 2 Effector Domains. FASEB Journal, 2009, 23, 873.6.	0.2	0
158	Drug Sensitivity and Alleleâ€specificity of Firstâ€line Osimertinib Resistance EGFR Mutations. FASEB Journal, 2020, 34, 1-1.	0.2	0